论文部分内容阅读
目的 检测Survivin和CD44v6在胃癌中的表达,以探讨二者在胃癌中表达的相关性及其与预后的关系。方法 利用组织芯片技术构建胃癌组织芯片,应用免疫组织化学S P法检测Survivin和CD44v6蛋白在胃癌中的表达。结果 胃癌中Survivin及CD44v6的总表达率分别为 58 6% (58 /99)和 35 4% (35 /99)。Survivin在早期胃癌中的表达显著高于进展期胃癌 (P<0 05 ),与胃癌的其它临床病理特征无相关性。CD44v6阳性表达与胃癌生长方式(P<0 001)、浸润深度 (P<0 05 )及淋巴结转移 (P<0 001 )密切相关。Sur vivin和CD44v6在胃癌中的表达无相关性(r=-0 065,P>0 05)。Survivin与胃癌患者的生存率无显著相关,而CD44v6表达阳性组 5年生存率(16 13% )显著低于CD44v6表达阴性组 5年生存率(60 67% ) (P<0 001 )。结论 Survivin和CD44v6在胃癌中均有过量表达。Survivin可能参与胃癌发生、发展的早期过程;而CD44v6阳性表达与胃癌的浸润和转移密切相关,同时可以提示胃癌的不良预后。
Objective To detect the expression of Survivin and CD44v6 in gastric cancer so as to investigate their correlation with prognosis. Methods Tissue microarray was used to construct gastric cancer tissue microarray. Immunohistochemical SP method was used to detect the expression of Survivin and CD44v6 in gastric cancer. Results The total expression rates of Survivin and CD44v6 in gastric cancer were 58 6% (58/99) and 35 4% (35/99), respectively. The expression of Survivin in early gastric cancer was significantly higher than that in advanced gastric cancer (P <0.05), which was not associated with other clinicopathological features of gastric cancer. The positive expression of CD44v6 was closely related to the growth pattern of gastric cancer (P <0.001), the depth of invasion (P <0.05) and lymph node metastasis (P <0.001). No correlation was found between Survivin and CD44v6 expression in gastric cancer (r = -0.065, P> 0.05). The survival rate of patients with gastric cancer was not significantly correlated with Survivin, but the 5-year survival rate of patients with positive expression of CD44v6 (16 13%) was significantly lower than that of patients with negative expression of CD44v6 (60 67%) (P 0 001). Conclusion Both Survivin and CD44v6 are overexpressed in gastric cancer. Survivin may be involved in the early process of gastric carcinogenesis and development. However, the positive expression of CD44v6 is closely related to the invasion and metastasis of gastric cancer, and can also indicate the poor prognosis of gastric cancer.